Hepatitis A vaccination coverage amongst people with Chronic Liver Disease in England (HEALD): protocol for a retrospective cohort study

Submission date	Recruitment status No longer recruiting	Prospectively registered		
11/09/2023		[X] Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
12/10/2023		[X] Results		
Last Edited	Condition category	[] Individual participant data		
27/01/2025	Digestive System			

Plain English summary of protocol

Background and study aims

Hepatitis A outbreaks in the United Kingdom are uncommon. Most people develop mild-to-moderate symptoms that resolve, without sequelae, within months. However, in high-risk groups, including those with underlying chronic liver disease, hepatitis A infection can be severe, with higher risk of mortality and morbidity.

The UK's public health body, the Health Security Agency and the English guidelines organisation, the National Institute of Health and Care Excellence, recommend pre-exposure hepatitis A vaccination given as two doses to people with chronic liver disease, regardless of its cause. There are currently no published reports of vaccination coverage in people with chronic liver disease in England, or internationally.

The study aims to describe hepatitis A vaccination coverage in adults with chronic liver disease in a UK primary care setting. To compare liver disease aetiology, sociodemographic characteristics and comorbidities in people who are and are not exposed to hepatitis A vaccine.

Who can participate?

Data used for the study will include all the individuals in England.

What does the study involve?

During the study GP data will be retrospectively analysed to get an understanding of hepatitis A vaccination coverage in adults with chronic liver disease in a UK primary care setting, comparing liver disease aetiology, sociodemographic characteristics and comorbidities in people who are and are not exposed to hepatitis A vaccine.

What are the possible benefits and risks of participating?

The results of the study will give a better understanding about how to administer the hepatitis A vaccine to people with chronic liver disease in the English population in the future.

Where is the study run from? Nuffield Department of Primary Health Care Sciences of the University of Oxford (UK)

When is the study starting and how long is it expected to run for? March 2022 to August 2024

Who is funding the study? GlaxoSmithKline (Belgium)

Who is the main contact? Prof. Simon de Lusignan, simon.delusignan@phc.ox.ac.uk

Contact information

Type(s)

Scientific

Contact name

Dr Bernardo Meza

ORCID ID

https://orcid.org/0000-0001-6551-5484

Contact details

Radcliffe Primary Care Building
Radcliffe Observatory Quarter
Woodstock Road
Oxford
United Kingdom
OX2 6GG
+44 1865 617855
bernardo.meza-torres@phc.ox.ac.uk

Type(s)

Principal investigator

Contact name

Prof Simon de Lusignan

Contact details

Radcliffe Primary Care Building Radcliffe Observatory Quarter Woodstock Road Oxford United Kingdom OX2 6GG +44 1865 617855 simon.delusignan@phc.ox.ac.uk

Type(s)

Public

Contact name

Dr Bernardo Meza

Contact details

Radcliffe Primary Care Building Radcliffe Observatory Quarter Woodstock Road Oxford United Kingdom OX2 6GG +44 1865 617855 bernardo.meza-torres@phc.ox.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

GSK ISS: 14309

Study information

Scientific Title

Hepatitis A vaccination coverage amongst people with Chronic Liver Disease in England (HEALD): protocol for a retrospective cohort sentinel network database study

Acronym

HEALD

Study objectives

This study fills this gap reporting ehpatitis A (Hep A) vaccine coverage in people with chronic liver disease (CLD), with a focus on whether there are disparities as to which people with CLD receive Hep A vaccination.

The study aim is to report Hep A vaccination coverage in people with CLD in English primary care and the predictors of receiving a single dose or full vaccination course. With the following objectives:

- 1. To report Hep A vaccination coverage in people with CLD by:
- a. Sociodemographic characteristics (e.g. age, gender, ethnicity, deprivation, obesity, smoking, alcohol consumption)
- b. CLD disease type (e.g. alcholic liver disease, chronic hepatitis B and C, Non alcoholic fatty liver disease).
- c. CLD complications (e.g. renal disease, ascites, liver failure and transplant, cardio-metabolic disease)

- d. Comorbidities and exposures (e.g. Cambridge Multimorbidity Score (CMMS), bile duct and colon cancers, at least three doses of COVID-19 vaccine, flu vaccination).
- 2. To report the predictors of one- and two-doses of Hep A vaccination in people with CLD.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 09/06/2022, Central University Research Ethics Committee (CUREC) at the University of Oxford (Boundary Brook House, Churchill Drive, Headington, Oxford, OX3 7GB, United Kingdom; +44 1865 616577; ethics@medsci.ox.ac.uk), ref: R80951/RE001

Study design

Retrospective cohort study

Primary study design

Observational

Study type(s)

Other

Health condition(s) or problem(s) studied

People with chronic liver disease, including alcohol-related liver disease (ALD), chronic hepatitis B infection (CH-B), chronic hepatitis C infection (CH-C), and non-alcoholic fatty liver disease (NAFLD)

Interventions

Using data from the Primary Care Sentinel Cohort (PCSC) of the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance centre (RSC) for the period between the 1st January 2012 and 31st December 2022. Data will be extracted retrospectively at the time of the start of the study.

Intervention Type

Other

Primary outcome(s)

Number of doses of hepatitis A vaccination measured using patient records at a single time point

Key secondary outcome(s))

There are no secondary outcome measures

Completion date

31/08/2024

Eligibility

Key inclusion criteria

We will include adults registered in general practices within the RSC network, with a diagnosis of CLD, as defined by our ontology, within the period between the 1st January 2012 and 31st December 2022. The following inclusion criteria will be applied:

People registered in the RSC general practices, aged 18 years of age and older, with a diagnosis of CLD. Our ontology for CLD includes: Alcoholic liver disease (ALD), chronic hepatitis B (CH-B), chronic hepatitis C (CH-C), non-alcoholic fatty liver disease, Wilson's Disease, haemochromatosis, autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).

Participant type(s)

Population

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Αll

Total final enrolment

13875

Key exclusion criteria

- 1. Patients with recorded contraindications to the Hep A vaccine (confirmed anaphylactic reaction to a previous dose of Hep A containing vaccine, or to any of its components).
- 2. Records of administration of post-infection or risk-of-infection immunoglobulins.

Date of first enrolment

06/06/2023

Date of final enrolment

06/06/2023

Locations

Countries of recruitment

United Kingdom

England

Wales

Study participating centre

Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences at the University of Oxford

Radcliffe Primary Care Building Radcliffe Observatory Quarter Woodstock Road Oxford United Kingdom OX2 6GG

Sponsor information

Organisation

University of Oxford

ROR

https://ror.org/052gg0110

Funder(s)

Funder type

Industry

Funder Name

GlaxoSmithKline Biologicals

Alternative Name(s)

GSK Belgium, GlaxoSmithKline Biologicals SA, GlaxoSmithKline Biologicals SAS, GlaxoSmithKline (GSK) Biologicals, GSK Biologicals, GSK

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Belgium

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a non-publicly available repository, at the ORCHID database hosted by the Nuffield Department of Primary Care Health Sciences at the University of Oxford (https://orchid.phc.ox.ac.uk/)

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results	version 5.2	04/12/2024	17/01/2025	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Protocol (preprint)		05/09/2023	15/09/2023	No	No